Ranibizumab (Lucentis, Novartis), another anti-VEGF drug, a fragment of a recombinant humanized IgG1 monoclonal antibody that inhibits all isoforms of the human VEGF-A, has been shown to be beneficial as an adjuvant treatment in neovascular glaucoma and rubeosis due to its antiangiogenic properties [9]. Here, VEGFA is linked to neovascular glaucoma.